Compare $MRKR vs $TCRX | Chartloom

Compare

$MRKR vs $TCRX

Marker Therapeutics Inc · TScan Therapeutics Inc

MRKR

Marker Therapeutics Inc

TCRX

TScan Therapeutics Inc

Compare $MRKR vs $TCRX

Comparing Marker Therapeutics Inc and TScan Therapeutics Inc

MRKRMarker Therapeutics Inc

TCRXTScan Therapeutics Inc

MRKRMarker Therapeutics Inc

Market cap

$16M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.16x

Rev growth (TTM)

-46.2%

YTD performance

-36.9%

52W performance

-10.0%

FCF yield

-60.2%

TCRXTScan Therapeutics Inc

Market cap

$16M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

8.85x

Rev growth (TTM)

2.2%

YTD performance

-76.7%

52W performance

-88.0%

FCF yield

-761.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

MRKR

TCRX

Detailed metrics comparison

MRKR

Marker Therapeutics Inc

TCRX

TScan Therapeutics Inc

Market Cap

MRKR$16M

TCRX$16M

Enterprise Value

MRKR$5M

TCRX$-52M

Price

MRKR$0.97

TCRX$0.24

P/E Ratio

MRKRN/A

TCRXN/A

P/S Ratio

MRKR6.93x

TCRX2.19x

EV/Sales

MRKR2.08x

TCRX-7.29x

EV/EBITDA

MRKR0.00x

TCRX0.00x

P/B Ratio

MRKR1.44x

TCRX0.31x

P/FCF Ratio

MRKRN/A

TCRXN/A

EV/FCF

MRKR-0.50x

TCRX0.44x

PEG Ratio

MRKRN/A

TCRXN/A

Forward P/E (NTM)

MRKRN/A

TCRXN/A

Forward P/S (NTM)

MRKR3.16x

TCRX8.85x

Revenue (TTM)

MRKR$2M

TCRX$7M

Revenue Growth (YoY)

MRKR-46.2%

TCRX2.2%

Forward Rev Growth

MRKR375.8%

TCRX42.6%

Gross Margin (TTM)

MRKR0.0%

TCRX0.0%

Operating Margin (TTM)

MRKR0.0%

TCRX0.0%

EBITDA Margin (TTM)

MRKR-284.3%

TCRX-1626.5%

Net Margin (TTM)

MRKR-236.6%

TCRX-1655.4%

FCF Margin (TTM)

MRKR-417.6%

TCRX-1665.6%

Net Income (TTM)

MRKR$-6M

TCRX$-118M

FCF (TTM)

MRKR$-10M

TCRX$-118M

EPS (TTM)

MRKR-$0.27

TCRX-$0.91

ROE (TTM)

MRKR-8086.0%

TCRX-10872.0%

ROA (TTM)

MRKR-6705.0%

TCRX-5447.0%

ROIC (TTM)

MRKR-8086.0%

TCRX-8356.0%

Cash

MRKR$11M

TCRX$100M

Debt

MRKR$0

TCRX$33M

Net Cash/Debt

MRKR$11M

TCRX$67M

Current Ratio (TTM)

MRKR6.03x

TCRX3.37x

Quick Ratio (TTM)

MRKR5.60x

TCRX3.23x

Debt/Equity (TTM)

MRKR0.00x

TCRX0.47x

Debt/Assets (TTM)

MRKR0.0%

TCRX0.0%

Interest Coverage (TTM)

MRKRN/A

TCRXN/A

Net Debt/EBITDA (TTM)

MRKR0.00x

TCRX0.00x

Beta

MRKR1.59

TCRX1.19

52W Performance

MRKR-10.0%

TCRX-88.0%

YTD Performance

MRKR-36.9%

TCRX-76.7%

% from 52W High

MRKR-60.5%

TCRX-90.7%

% from 52W Low

MRKR15.7%

TCRX6.1%

Asset Turnover (TTM)

MRKR0.20x

TCRX0.03x

FCF Yield (TTM)

MRKR-60.2%

TCRX-761.5%

Earnings Yield (TTM)

MRKR-34.1%

TCRX-756.8%

Dividend Yield (TTM)

MRKRN/A

TCRXN/A

Rule of 40

MRKR-463.8

TCRX-1,663.4

EV/GP/RG

MRKRN/A

TCRXN/A

Ticker research

View MRKR research View TCRX research

Metric	MRKR Marker Therapeutics Inc	TCRX TScan Therapeutics Inc
Market & Valuation
Market Cap	$16M	$16M
Enterprise Value	$5M	$-52M
Price	$0.97	$0.24
P/E Ratio	N/A	N/A
P/S Ratio	6.93x	2.19x
EV/Sales	2.08x	-7.29x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.44x	0.31x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.50x	0.44x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.16x	8.85x
Revenue & Growth
Revenue (TTM)	$2M	$7M
Revenue Growth (YoY)	-46.2%	2.2%
Forward Rev Growth	375.8%	42.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-284.3%	-1626.5%
Net Margin (TTM)	-236.6%	-1655.4%
FCF Margin (TTM)	-417.6%	-1665.6%
Net Income (TTM)	$-6M	$-118M
FCF (TTM)	$-10M	$-118M
EPS (TTM)	-$0.27	-$0.91
ROE (TTM)	-8086.0%	-10872.0%
ROA (TTM)	-6705.0%	-5447.0%
ROIC (TTM)	-8086.0%	-8356.0%
Financial Health
Cash	$11M	$100M
Debt	$0	$33M
Net Cash/Debt	$11M	$67M
Current Ratio (TTM)	6.03x	3.37x
Quick Ratio (TTM)	5.60x	3.23x
Debt/Equity (TTM)	0.00x	0.47x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.59	1.19
52W Performance	-10.0%	-88.0%
YTD Performance	-36.9%	-76.7%
% from 52W High	-60.5%	-90.7%
% from 52W Low	15.7%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.20x	0.03x
FCF Yield (TTM)	-60.2%	-761.5%
Earnings Yield (TTM)	-34.1%	-756.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-463.8	-1,663.4
EV/GP/RG	N/A	N/A
Ticker research	View MRKR research	View TCRX research

Valuation

P/S Ratio

TCRX

2.19x

MRKR

6.93x

EV/FCF

MRKR

-0.50x

TCRX

0.44x

Growth & revenue

Revenue Growth TTM

TCRX

2.2%

MRKR

-46.2%

Forward Revenue Growth

MRKR

375.8%

TCRX

42.6%

Profitability & performance

Gross Margin

MRKR

0.0%

TCRX

0.0%

ROE

MRKR

-8086.0%

TCRX

-10872.0%

FCF Yield %

MRKR

-60.2%

TCRX

-761.5%

52-Week Performance

MRKR

-10.0%

TCRX

-88.0%

Detailed metrics comparison

MRKR

Marker Therapeutics Inc

TCRX

TScan Therapeutics Inc

Market Cap

MRKR$16M

TCRX$16M

Enterprise Value

MRKR$5M

TCRX$-52M

Price

MRKR$0.97

TCRX$0.24

P/E Ratio

MRKRN/A

TCRXN/A

P/S Ratio

MRKR6.93x

TCRX2.19x

EV/Sales

MRKR2.08x

TCRX-7.29x

EV/EBITDA

MRKR0.00x

TCRX0.00x

P/B Ratio

MRKR1.44x

TCRX0.31x

P/FCF Ratio

MRKRN/A

TCRXN/A

EV/FCF

MRKR-0.50x

TCRX0.44x

PEG Ratio

MRKRN/A

TCRXN/A

Forward P/E (NTM)

MRKRN/A

TCRXN/A

Forward P/S (NTM)

MRKR3.16x

TCRX8.85x

Revenue (TTM)

MRKR$2M

TCRX$7M

Revenue Growth (YoY)

MRKR-46.2%

TCRX2.2%

Forward Rev Growth

MRKR375.8%

TCRX42.6%

Gross Margin (TTM)

MRKR0.0%

TCRX0.0%

Operating Margin (TTM)

MRKR0.0%

TCRX0.0%

EBITDA Margin (TTM)

MRKR-284.3%

TCRX-1626.5%

Net Margin (TTM)

MRKR-236.6%

TCRX-1655.4%

FCF Margin (TTM)

MRKR-417.6%

TCRX-1665.6%

Net Income (TTM)

MRKR$-6M

TCRX$-118M

FCF (TTM)

MRKR$-10M

TCRX$-118M

EPS (TTM)

MRKR-$0.27

TCRX-$0.91

ROE (TTM)

MRKR-8086.0%

TCRX-10872.0%

ROA (TTM)

MRKR-6705.0%

TCRX-5447.0%

ROIC (TTM)

MRKR-8086.0%

TCRX-8356.0%

Cash

MRKR$11M

TCRX$100M

Debt

MRKR$0

TCRX$33M

Net Cash/Debt

MRKR$11M

TCRX$67M

Current Ratio (TTM)

MRKR6.03x

TCRX3.37x

Quick Ratio (TTM)

MRKR5.60x

TCRX3.23x

Debt/Equity (TTM)

MRKR0.00x

TCRX0.47x

Debt/Assets (TTM)

MRKR0.0%

TCRX0.0%

Interest Coverage (TTM)

MRKRN/A

TCRXN/A

Net Debt/EBITDA (TTM)

MRKR0.00x

TCRX0.00x

Beta

MRKR1.59

TCRX1.19

52W Performance

MRKR-10.0%

TCRX-88.0%

YTD Performance

MRKR-36.9%

TCRX-76.7%

% from 52W High

MRKR-60.5%

TCRX-90.7%

% from 52W Low

MRKR15.7%

TCRX6.1%

Asset Turnover (TTM)

MRKR0.20x

TCRX0.03x

FCF Yield (TTM)

MRKR-60.2%

TCRX-761.5%

Earnings Yield (TTM)

MRKR-34.1%

TCRX-756.8%

Dividend Yield (TTM)

MRKRN/A

TCRXN/A

Rule of 40

MRKR-463.8

TCRX-1,663.4

EV/GP/RG

MRKRN/A

TCRXN/A

Ticker research

View MRKR research View TCRX research

Metric	MRKR Marker Therapeutics Inc	TCRX TScan Therapeutics Inc
Market & Valuation
Market Cap	$16M	$16M
Enterprise Value	$5M	$-52M
Price	$0.97	$0.24
P/E Ratio	N/A	N/A
P/S Ratio	6.93x	2.19x
EV/Sales	2.08x	-7.29x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.44x	0.31x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.50x	0.44x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.16x	8.85x
Revenue & Growth
Revenue (TTM)	$2M	$7M
Revenue Growth (YoY)	-46.2%	2.2%
Forward Rev Growth	375.8%	42.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-284.3%	-1626.5%
Net Margin (TTM)	-236.6%	-1655.4%
FCF Margin (TTM)	-417.6%	-1665.6%
Net Income (TTM)	$-6M	$-118M
FCF (TTM)	$-10M	$-118M
EPS (TTM)	-$0.27	-$0.91
ROE (TTM)	-8086.0%	-10872.0%
ROA (TTM)	-6705.0%	-5447.0%
ROIC (TTM)	-8086.0%	-8356.0%
Financial Health
Cash	$11M	$100M
Debt	$0	$33M
Net Cash/Debt	$11M	$67M
Current Ratio (TTM)	6.03x	3.37x
Quick Ratio (TTM)	5.60x	3.23x
Debt/Equity (TTM)	0.00x	0.47x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.59	1.19
52W Performance	-10.0%	-88.0%
YTD Performance	-36.9%	-76.7%
% from 52W High	-60.5%	-90.7%
% from 52W Low	15.7%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.20x	0.03x
FCF Yield (TTM)	-60.2%	-761.5%
Earnings Yield (TTM)	-34.1%	-756.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-463.8	-1,663.4
EV/GP/RG	N/A	N/A
Ticker research	View MRKR research	View TCRX research